To further examine the mechanisms of therapeutic acetylcholinesterase inhibitors currently utilized in the treatment of Alzheimer's disease, Takada-Takatori et al [52] reported that the PI3K/Akt signaling pathway is involved in the neuroprotective effects of donepezil and galanthamine, but not that of tacrine. The gene discussed is AKT1; the disease is Alzheimer disease.